475 related articles for article (PubMed ID: 29036412)
1. Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma.
Kickingereder P; Neuberger U; Bonekamp D; Piechotta PL; Götz M; Wick A; Sill M; Kratz A; Shinohara RT; Jones DTW; Radbruch A; Muschelli J; Unterberg A; Debus J; Schlemmer HP; Herold-Mende C; Pfister S; von Deimling A; Wick W; Capper D; Maier-Hein KH; Bendszus M
Neuro Oncol; 2018 May; 20(6):848-857. PubMed ID: 29036412
[TBL] [Abstract][Full Text] [Related]
2. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
[TBL] [Abstract][Full Text] [Related]
3. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V
Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505
[TBL] [Abstract][Full Text] [Related]
4. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H
Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594
[TBL] [Abstract][Full Text] [Related]
5. Analysis of heterogeneity of peritumoral T2 hyperintensity in patients with pretreatment glioblastoma: Prognostic value of MRI-based radiomics.
Choi Y; Ahn KJ; Nam Y; Jang J; Shin NY; Choi HS; Jung SL; Kim BS
Eur J Radiol; 2019 Nov; 120():108642. PubMed ID: 31546124
[TBL] [Abstract][Full Text] [Related]
6. Radiomic MRI Phenotyping of Glioblastoma: Improving Survival Prediction.
Bae S; Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Radiology; 2018 Dec; 289(3):797-806. PubMed ID: 30277442
[TBL] [Abstract][Full Text] [Related]
7. Radiomics may increase the prognostic value for survival in glioblastoma patients when combined with conventional clinical and genetic prognostic models.
Choi Y; Nam Y; Jang J; Shin NY; Lee YS; Ahn KJ; Kim BS; Park JS; Jeon SS; Hong YG
Eur Radiol; 2021 Apr; 31(4):2084-2093. PubMed ID: 33006658
[TBL] [Abstract][Full Text] [Related]
8. Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features.
Kickingereder P; Bonekamp D; Nowosielski M; Kratz A; Sill M; Burth S; Wick A; Eidel O; Schlemmer HP; Radbruch A; Debus J; Herold-Mende C; Unterberg A; Jones D; Pfister S; Wick W; von Deimling A; Bendszus M; Capper D
Radiology; 2016 Dec; 281(3):907-918. PubMed ID: 27636026
[TBL] [Abstract][Full Text] [Related]
9. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
Kickingereder P; Götz M; Muschelli J; Wick A; Neuberger U; Shinohara RT; Sill M; Nowosielski M; Schlemmer HP; Radbruch A; Wick W; Bendszus M; Maier-Hein KH; Bonekamp D
Clin Cancer Res; 2016 Dec; 22(23):5765-5771. PubMed ID: 27803067
[TBL] [Abstract][Full Text] [Related]
10. Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma.
Sasaki T; Kinoshita M; Fujita K; Fukai J; Hayashi N; Uematsu Y; Okita Y; Nonaka M; Moriuchi S; Uda T; Tsuyuguchi N; Arita H; Mori K; Ishibashi K; Takano K; Nishida N; Shofuda T; Yoshioka E; Kanematsu D; Kodama Y; Mano M; Nakao N; Kanemura Y
Sci Rep; 2019 Oct; 9(1):14435. PubMed ID: 31594994
[TBL] [Abstract][Full Text] [Related]
11. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
12. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
[TBL] [Abstract][Full Text] [Related]
13. Development of A Radiomic Model for
Doniselli FM; Pascuzzo R; Agrò M; Aquino D; Anghileri E; Farinotti M; Pollo B; Paterra R; Cuccarini V; Moscatelli M; DiMeco F; Sconfienza LM
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203308
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme.
Chen X; Fang M; Dong D; Liu L; Xu X; Wei X; Jiang X; Qin L; Liu Z
Acad Radiol; 2019 Oct; 26(10):1292-1300. PubMed ID: 30660472
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
17. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
18. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
19. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
20. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W
Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
